• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Appoints Christine Mellon as Chief People Officer

    2/22/21 8:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email

    MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Christine Mellon has joined the company as Executive Vice President, Chief People Officer. Bringing more than 25 years of human resources, organizational, and cultural transformation leadership, Ms. Mellon will lead human resources functions, employee environments, and internal communications for Omnicell’s global operations.

    “As Omnicell continues to transform the pharmacy care delivery model to deliver on the vision of Autonomous Pharmacy, Christine’s role will be pivotal to shaping our people organization to support our business transformation to a technology-enabled services offering,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell.

    Ms. Mellon’s responsibilities include talent management, employee culture and engagement, diversity and inclusion, global rewards, business partnering, and real estate.

    Prior to joining Omnicell, Ms. Mellon served as Chief Human Resources Officer (CHRO) with CSG, where she transformed human resources into a valued strategic asset and led culture change efforts. She was previously Vice President, Human Capital Management for Oracle, where she consulted with North American CHRO clients, providing human capital strategic support, thought leadership, and HR technology guidance. Ms. Mellon has also served in HR leadership roles for Echostar and Cigna, among others.

    “I’m excited to join Omnicell in its mission to be the most trusted partner for medication management,” said Ms. Mellon. “I look forward to building a dynamic global team committed to delivering the technology, intelligence, and ‘as a service’ offerings to help our customers navigate the evolving complexities of medication management.”

    About Omnicell

    Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

    OMCL-G

    Get the next $OMCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    2/4/2026$70.00Neutral → Buy
    BofA Securities
    1/8/2026$60.00Sector Weight → Overweight
    KeyBanc Capital Markets
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    3/18/25 4:13:27 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Omnicell upgraded by BofA Securities with a new price target

    BofA Securities upgraded Omnicell from Neutral to Buy and set a new price target of $70.00

    2/4/26 8:25:37 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Omnicell from Sector Weight to Overweight and set a new price target of $60.00

    1/8/26 8:12:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

    5/14/25 8:50:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO Lipps Randall A sold $470,000 worth of shares (10,000 units at $47.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    7/17/26 4:05:07 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    President & COO Njoku Nnamdi was granted 12,309 shares, increasing direct ownership by 8% to 167,094 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    7/6/26 4:05:10 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Director Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/26 4:05:19 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/ev

    7/13/26 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Nnamdi Njoku Appointed President of Omnicell

    Njoku continues to lead global operations and advance Omnicell's innovation and AI platform strategy; Randall Lipps continues to serve as Chief Executive Officer and Chairman of the Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer (COO), while Randall Lipps will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the long-term evolution of Omnic

    7/1/26 8:15:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

    Seasoned healthcare executive with deep expertise in specialty pharmacy operations named Senior Vice President and General Manager Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Dan Mandoli, a seasoned healthcare executive with more than 30 years of leadership across pharmacy operations and specialty pharmacy services, has joined the Company as Senior Vice President and General Manager, Specialty Pharmacy Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608580918/en/Omnicell Welcomes Dan

    6/8/26 8:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    View All

    Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer

    Newly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry

    4/29/26 8:00:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer

    Seasoned leader brings more than 30 years of experience driving growth for healthcare and technology companies Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer of the Company, effective August 26, 2025. Mr. Radford succeeds Nchacha Etta, who will be stepping down from the role, as announced earlier this year. Mr. Etta will remain with the Company in an advisory role through November 2025 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release

    8/25/25 4:05:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

    The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

    9/25/24 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    SEC Filings

    View All

    SEC Form S-8 filed by Omnicell Inc.

    S-8 - OMNICELL, INC. (0000926326) (Filer)

    7/7/26 4:02:41 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - OMNICELL, INC. (0000926326) (Filer)

    7/1/26 8:27:47 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SD filed by Omnicell Inc.

    SD - OMNICELL, INC. (0000926326) (Filer)

    5/29/26 4:04:15 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    12/11/23 9:36:42 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    9/11/23 1:33:44 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    2/9/23 11:27:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Financials

    Live finance-specific insights

    View All

    Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/ev

    7/13/26 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Announces First Quarter 2026 Financial Results

    Omnicell delivers strong first quarter 2026 financial results Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance Customer engagement underway for Omnicell Titan XT and OmniSphere Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026. First quarter results reflected strong execution across the business, supported by demand for Omnicell's connected device portfolio and solid performance across the Company's core points of care solutions. We believe that performance during the quarte

    4/28/26 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 9381205. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/event

    4/13/26 5:00:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology